Esaote is presenting its Prostate Attention Map (PAM) technology, now available on its new MyLab E85 GTS ultrasound system, at the 2026 European Association of Urology (EAU) congress in London.
PAM automatically analyzes prostate multiparametric MRI volumes and identifies suspicious regions of interest to assist urologists with targeted biopsy guidance and decision-making, according to the company. The technology is integrated into Esaote's UroFusion software, which is designed to provide focal guidance during prostate-targeted biopsies, the firm said.
At the congress, Esaote is also presenting MyLab C30 GTS, a portable system designed to extend high image quality across different examination settings. The two new systems expand the company's guided therapy solutions line, Esaote said.
